ACADIA to Host Conference Call and Webcast on Tuesday, November 6,2018, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Oct. 23, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its financial results for the thirdquarter ended September 30, 2018 on Tuesday, November 6, 2018, after theU.S. financial markets close. ACADIA’s management will host a conferencecall and webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Timeto discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 855-638-4820 forparticipants in the United States or Canada and 443-877-4067 forinternational callers (reference passcode 3659459). A telephone replayof the conference call may be accessed through November 20, 2018 bydialing 855-859-2056 for callers in the United States or Canada and404-537-3406 for international callers (reference passcode 3659459). Theconference call also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until November20, 2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has developed and iscommercializing the first and only medicine approved for the treatmentof hallucinations and delusions associated with Parkinson’s diseasepsychosis. In addition, ACADIA has ongoing clinical development effortsin additional areas with significant unmet need, includingdementia-related psychosis, schizophrenia inadequate response,schizophrenia-negative symptoms, major depressive disorder and Rettsyndrome. This press release and further information about ACADIA can befound at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements regarding the timing of future events. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development, approval andcommercialization. For a discussion of these and other factors, pleaserefer to ACADIA’s annual report on Form 10-K for the year ended December31, 2017 as well as ACADIA’s subsequent filings with the Securities andExchange Commission. You are cautioned not to place undue reliance onthese forward-looking statements, which speak only as of the datehereof. This caution is made under the safe harbor provisions of thePrivate Securities Litigation Reform Act of 1995. All forward-lookingstatements are qualified in their entirety by this cautionary statementand ACADIA undertakes no obligation to revise or update this pressrelease to reflect events or circumstances after the date hereof, exceptas required by law.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com